◀ Back to SRC
CXCL16 — SRC
Text-mined interactions from Literome
Chandrasekar et al., J Biol Chem 2005
:
Src kinase inhibitors PP1 and PP2, phosphatidylinositol 3-kinase (PI3K) inhibitors wortmannin and LY294002, Akt inhibitor, the c-Jun N-terminal kinase (JNK) inhibitor SP600125, antisense JNK and dominant negative MyD88, interleukin-1 receptor associated kinase ( IRAK)-1, IRAK4, and phosphatidylinositol 3-kinase expression all
attenuated IL-18 mediated AP-1 binding and reporter activity,
CXCL16 promoter-reporter activity, and CXCL16 expression
Lin et al., J Immunol 2006
:
Thrombin induced increase in
IL-8/CXCL8-Luc activity was
inhibited by the dominant negative mutant of
c-Src and the cells transfected with the kappaB site mutation of the IL-8/CXCL8 construct
Petrai et al., Int J Biochem Cell Biol 2008
:
In cells expressing CXCR3-A,
CXCL10 ( IP-10 ) at nanomolar concentrations
induced activation of ERK, Akt, and
Src , as previously described in human vascular pericytes